Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LAB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStandard BioTools reports Q1 2026 results, updates full-year revenue outlook
Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read
Key Changes
-
high
Company disclosed first quarter 2026 financial results through press release. Specific revenue, earnings, and other metrics are in the attached exhibit, not the 8-K body itself.
Item 2.02 verify on EDGAR → -
high
Management provided updated full-year 2026 revenue guidance. This forward-looking outlook was furnished but not filed, limiting legal liability for projections.
Item 7.01 verify on EDGAR → -
medium
The 8-K references financial information by incorporation only. Investors must review the press release exhibit (99.1) for actual quarterly numbers and guidance details.
8-K: Financial Results verify on EDGAR →
Summary
Standard BioTools announced its first quarter 2026 financial results and updated its full-year revenue outlook on May 5, 2026. The 8-K filing itself contains minimal detail, instead incorporating information by reference from an attached press release.
The company used the standard practice of furnishing rather than filing this information, which reduces legal exposure for forward-looking statements while still satisfying disclosure requirements. Retail investors should note that the actual quarterly performance metrics—revenue, earnings, cash flow—are not in the 8-K body.
You must review Exhibit 99.1 to see whether the company beat, met, or missed expectations and how management adjusted full-year guidance. The distinction between furnished and filed information is procedural but signals management's caution around forward-looking projections. Watch for analyst reactions to the guidance update and whether the company provides additional detail on its earnings call. Any material divergence between Q1 results and prior expectations could drive near-term stock movement.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Standard BioTools disclosed Q1 2026 financial results via press release and updated full-year 2026 revenue outlook.
Added in current filing · verify on EDGAR →
On May 5, 2026, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months ended March 31, 2026.
The company announced its first quarter 2026 financial results through a press release. The 8-K incorporates the financial results by reference but does not provide specific numbers in the filing body itself. The actual financial metrics would be found in the attached press release (Exhibit 99.1).
Added in current filing · verify on EDGAR →
The information set forth in the press release, except for the information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward-looking statement disclaimer, is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.
The company provided updated full-year 2026 revenue guidance in the press release. Notably, this forward-looking guidance is explicitly excluded from incorporation by reference into the 8-K, meaning it is furnished but not filed, which limits legal liability for forward-looking statements.
Event · Item 7.01 — Regulation FD Disclosure
Regulation FD disclosure incorporating forward-looking statements and revenue outlook by reference; no material details provided in 8-K body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.
The company filed a Regulation FD disclosure that incorporates by reference information about full year 2026 revenue outlook and company description. The actual content is not included in the 8-K body itself, making it impossible to assess materiality or specifics of any guidance update.
Event · Item 9.01 — Financial Statements and Exhibits
Standard BioTools filed an 8-K referencing Items 2.02 and 7.01 with a press release exhibit; no material business event disclosed in body.
Added in current filing · verify on EDGAR →
The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
The 8-K references Item 2.02 (typically financial results) and Item 7.01 (regulation FD disclosure) with a press release dated May 5, 2026. The filing body provides no detail on the actual event; the press release exhibit would contain the substantive disclosure. The boilerplate language indicates this information is furnished, not filed, meaning it carries reduced legal liability.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify